At ProPharma Group, our teams have supported a variety of clinical studies in the oncology trial space. Additionally, we understand the burdens oncology patients face and can coordinate with our in-house decentralized clinical trial services team to help identify and eliminate them so that patients remain able to participate for the duration of your study.
Oncology Expertise by Indication
ProPharma Group has a unique combination of experience across both early phase oncology and immuno-oncology clinical trials. Our clinical trial leaders (CRAs, Clinical Leads, Clinical PMs, Site Start Up Leads, etc.) have supported over 115 oncology programs across all phases of development and many novel therapies throughout their careers.
We have supported clinical trials in both adult and pediatric populations across a variety of oncology and hematology indications:
|
|
Oncology Resources
|
|
A Statistically Leveraged Dose Escalation Study Design (BOIN)Determining the recommended phase 2 dose of a study drug is a critical step in the life cycle of a clinical drug’s development. The Bayesian Optimal Interval Design (BOIN) design improves upon both of these items while also facilitating quick and simple decisions regarding escalation, de-escalation, or maintaining the current study dose.
|
Get Expert Guidance for Your Oncology Clinical Trials
At ProPharma Group, our experts work as an extension of your team, bringing you immediate resources that align with your processes and environment. We bring a consultative approach to your oncology studies and will identify potential challenges to help craft strategies and solutions before you are confronted with them during a regulatory assessment.
Contact us to connect with a member of our team and tell us how we can help support your oncology trial.